Japan relies almost entirely on China for the APIs of β-lactam antibiotics. These drugs are essential for treating infectious diseases…
HOME > LATEST
LATEST
-
BUSINESS Novartis Adjusts Entresto Shipments Ahead of Price Hike in Off-Year Revision
March 7, 2025
-
BUSINESS Off-Year Revision Is Problematic, Leads to Hesitation in Investment: Novo CEO
March 7, 2025
-
REGULATORY Takeda’s Livmarli, BMS’s Camzyos, and More Inch Closer to Japan Approval
March 7, 2025
-
BUSINESS Keytruda Tops Japan Drug Ranking for 17th Months on End: Encise
March 7, 2025
-
BUSINESS Maruishi Files Midazolam Oral Syrup for Pediatric Use
March 7, 2025
-
BUSINESS J&J Files Tremfya SC Induction Regimen for UC in Japan
March 7, 2025
-
BUSINESS Novo Bolsters Wegovy Label in Japan with CV Outcome Data
March 6, 2025
-
REGULATORY New LDP Project Team Holds Hearing for Govt’s Startup Measures
March 6, 2025
-
ORGANIZATION Cough Drug Asverin Tops Supply Shortage Ranking in Japan: P-Cubed Survey
March 6, 2025
-
BUSINESS AZ Wins Certification to Allow Use of Pseudonymized Medical Info
March 6, 2025
-
REGULATORY CAR-T Therapies Subject to Label Revision over Lymphoid Neoplasm Risk
March 6, 2025
-
REGULATORY Safety-Related Label Revision Ordered for Trulicity, CP Inhibitors, and More
March 6, 2025
-
BUSINESS DMD Cell Therapy Accepted for FDA Review: Capricor/Nippon Shinyaku
March 6, 2025
-
ACADEMIA NCCH Launches Pilot for Online Screening of Clinical Trial Participants
March 6, 2025
-
REGULATORY MHLW Taking Applications for Subsidies to Support Generic Consolidation, Biosimilars
March 6, 2025
-
REGULATORY Takeda’s Livmarli, BMS’s Camzyos and More Up for MHLW Panel Review on March 6
February 21, 2025
-
REGULATORY PMD Act Set for Amendments Covering Issues Unaddressed over Past Decade: MHLW Official
February 4, 2025
-
BUSINESS Ono Axes ONO-2910 Peripheral Neuropathy Program and More
February 4, 2025
-
BUSINESS Mochida President Hails Govt Initiatives to Drive Biosimilar Uptake
February 4, 2025
-
BUSINESS Domestic Sites Approved for Meiji’s COVID Vaccine Kostaive
February 4, 2025
ページ
Your company’s employer brand is your reputation as an employer and is crucial in attracting top talent. Some reputations are just not good; they may or not be deserved. That is just the perception in the market. Years ago there…
A Japanese health ministry panel on December 26 wrapped up its discussions on the next amendment of the Pharmaceuticals and…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s key reimbursement policy panel on December 25 approved an outline of the FY2025 drug price revision, finalizing plans to…
For the first time in many years, Japan appeared to have pivoted to a pro-innovation path with the FY2024 drug pricing reform. All eyes were apparently on this course change as seen in this year’s most-read story list, though the…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…